###begin article-title 0
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
Genetic factors influence an individual's risk for developing neovascular age-related macular degeneration (AMD), a leading cause of irreversible blindness. Previous studies on the potential genetic link between AMD and vascular endothelial growth factor (VEGF), a key regulator of angiogenesis and vascular permeability, have yielded conflicting results. In the present case-control association study, we aimed to determine whether VEGF or its main receptor tyrosine kinase VEGFR-2 is genetically associated with neovascular AMD.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 140 147 140 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 403 408 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 425 432 425 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
A total of 515 Caucasian patients with neovascular AMD and 253 ethically-matched controls were genotyped for polymorphisms in the VEGFA and VEGFR-2 genes. A tagging single nucleotide polymorphism (tSNP) approach was employed to cover each gene plus two kilobases on each side, spanning the promoter and 3' untranslated regions. SNPs with a minimum allele frequency of 10% were covered by seven tSNPs in VEGFA and 20 tSNPs in VEGFR-2. Two VEGFA SNPs previously linked with AMD,  and , were also analyzed.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
The 29 VEGFA and VEGFR-2 SNPs analyzed in our cohort demonstrated no significant association with neovascular AMD. A single rare haplotype in the VEGFR-2 gene was associated with the presence of neovascular AMD (p=0.034).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 345 352 345 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
This study is the first to investigate the association of VEGFR-2 polymorphisms with AMD and evaluates VEGFA genetic variants in the largest neovascular AMD cohort to date. Despite the angiogenic and permeability-enhancing effects of VEGF/VEGFR-2 signaling, we found minimal evidence of a significant link between polymorphisms in the VEGFA and VEGFR-2 genes and neovascular AMD.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 320 323 320 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 344 355 344 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2/HTRA1</italic>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 446 449 446 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB</italic>
###xml 475 477 475 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 513 515 513 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 639 644 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in individuals over the age of 50 in the Western world [1]. In addition to dietary and environmental risk factors, genetics influences AMD susceptibility [2]. Recently, single nucleotide polymorphisms (SNPs) in the complement factor H (CFH) gene [3-5] and the ARMS2/HTRA1 locus [6,7] have been strongly linked to AMD. Common variants in the complement factor B (CFB)/complement component 2 (C2) [8,9] and complement component 3 (C3) [10-13] genes have also been associated with presence of AMD. Vascular endothelial growth factor (VEGF), coded for by the VEGFA gene, is a key mediator of angiogenesis and vascular permeability. Thus, VEGF is a logical candidate for genetically influencing AMD susceptibility, based on its functional relevance to AMD pathophysiology.
###end p 10
###begin p 11
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
VEGF plays a key role in the angiogenesis, vascular leakage, and inflammation that is characteristic of the neovascular form of advanced AMD [14]. In recent years, the VEGF signaling pathway has been targeted for inhibition therapy to treat choroidal neovascularization secondary to AMD [15]. VEGF regulates angiogenesis in the vascular endothelium through the high-affinity receptor tyrosine kinases VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1, KDR) [16]. Of these two receptors, VEGFR-2 is responsible for the majority of the angiogenic and permeability-enhancing effects of VEGF [17,18]. VEGFR-1 regulates VEGF activity in the vascular endothelium by preventing VEGF/VEGFR-2 binding [17].
###end p 11
###begin p 12
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 712 719 712 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 1065 1070 1065 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 1074 1081 1074 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
A relationship between the VEGFA and VEGFR-2 genes and neovascular AMD seems plausible, given the role of choroidal neovascularization in the pathophysiology of late-stage AMD and the importance of the receptor VEGFR-2 in the VEGF-signaling pathways that modulate angiogenesis and vascular permeability. Several small-scale case-control studies have reported associations between various SNPs in VEGFA and AMD [18-21], but these results have not been confirmed by subsequent studies [22-24]. While a recent analysis of VEGFA SNPs showed no associations with neovascular AMD, it did suggest that a three-SNP VEGFA haplotype increased the risk of neovascular AMD [25]. To our knowledge, the potential link between VEGFR-2 and AMD has not been investigated. In this study, we focused on neovascular AMD, as its positive response to anti-VEGF therapy implicates the VEGF pathway in the pathogenesis of this AMD subtype. Using a tagging SNP (tSNP) approach in a large cohort of neovascular AMD patients, we aimed to determine if a genetic association exists between the VEGFA or VEGFR-2 genes and neovascular AMD.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Subjects
###end title 14
###begin p 15
###xml 92 97 <span type="species:ncbi:9606">Human</span>
###xml 339 351 <span type="species:ncbi:9606">participants</span>
###xml 480 492 <span type="species:ncbi:9606">Participants</span>
###xml 550 558 <span type="species:ncbi:9606">patients</span>
This retrospective case-control association study was approved by the Washington University Human Research Protection Office and the Barnes Retina Institute Study Center. Research adhered to the tenets of the Declaration of Helsinki and was conducted in accordance with Health Insurance Portability and Accountability Act regulations. All participants were enrolled from the clinical offices of the Barnes Retina Institute, and informed consent was obtained before participation. Participants were identified through chart review, and only Caucasian patients with a diagnosis of neovascular AMD were included. Controls were identified as having no signs of AMD and were recruited from the same locations.
###end p 15
###begin p 16
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 128 139 <span type="species:ncbi:9606">participant</span>
A total of 768 patients were genotyped for SNPs in the VEGFA and VEGFR-2 genes using DNA extracted from mouthwash samples. Each participant provided buccal tissue samples by expectorating into 50 ml conical tubes (Falcon; BD Biosciences, San Jose, CA) after vigorously rinsing for 30 s with approximately 20 ml Scope mouthwash (Procter & Gamble, Cincinnati, OH). Genomic DNA was prepared from the collected buccal cells using the Gentra Puregene Buccal Cell Kit (Qiagen, Valencia, CA).
###end p 16
###begin title 17
Tagging single nucleotide polymorphism selection
###end title 17
###begin p 18
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 490 495 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 506 513 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 654 666 <span type="species:ncbi:9606">participants</span>
We employed a tSNP approach to cover the VEGFA and VEGFR-2 genes plus two kilobases (kb) on each side, including the promoter and 3' untranslated regions. Using  Project Build 36, we identified the SNPs in each gene with a minimum allele frequency (MAF) of 10% [18,22]. The minimum r2 value was set to 0.80, and genotypes for the Centre d'Etude du Polymorphisme Humain (CEPH) from Utah (CEU) population (Utah residents with ancestry from northern and western Europe) were used. We selected VEGFA tSNPs and VEGFR-2 tSNPs covering the HapMap-identified SNPs through the  algorithm. Using Sequenom MassARRAY technology (Sequenom Inc., San Diego, CA), study participants were genotyped for these tSNPs, as well as for two additional SNPs ( and ) previously associated with AMD [19,20].
###end p 18
###begin title 19
Data analysis
###end title 19
###begin p 20
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
Descriptive statistics for all demographic and clinical variables were calculated, and comparisons were made using the ANOVA test for means with continuous data (e.g., age) and the chi-square test for categorical data (e.g., gender). Genotyping data was loaded into  in linkage format to generate allele frequencies, ratios, and p values based on a chi-square test for association of alleles [26]. The Hardy-Weinberg equilibrium test was used to confirm that genotypes fell within a standard distribution. Genotype distributions were analyzed by logistic regression, incorporating adjustments for age and gender. Haplotype blocks encompassing the tested SNPs were defined by 95% confidence intervals and were predicted using Haploview. Statistics were performed with SPSS (version 17; SPSS Inc., Chicago, IL). For all statistical analyses, p<0.05 was considered to be statistically significant, and multiple comparisons were adjusted for by the Bonferroni correction.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 326 333 326 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Using HapMap and Tagger for tSNP selection, we identified seven VEGFA tSNPs and 22 VEGFR-2 tSNPs to cover both genes. Because two assays failed design, 20 tSNPs in VEGFR-2 were selected for genotyping. The two failed tSNPs correlated poorly with other SNPs, and alternative SNPs could not be chosen. The 20 genotyped tSNPs in VEGFR-2 had a mean r2 of 0.97 and captured 44 of the 46 SNPs with a MAF greater than 10%.
###end p 22
###begin p 23
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 406 413 406 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 624 631 624 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 689 696 689 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 938 945 938 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 1082 1089 1082 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 1095 1102 1095 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 1172 1179 1172 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
A total of 515 Caucasian patients with neovascular AMD and 253 ethnically-matched controls were genotyped for this study. Cases and controls had mean ages of 79.2 and 69.3 years, respectively (p<0.001). The case cohort consisted of a lower percentage of males (33.6%) than did the control cohort (43.9%; p=0.005). Adjustments for age and gender were incorporated in the genotype analysis of both VEGFA and VEGFR-2. All analyzed SNPs conformed to Hardy-Weinberg equilibrium in both the case and control populations. Allele distributions did not differ significantly between cases and controls for any of the nine VEGFA SNPs (Table 1). According to the genotype distribution for these SNPs (Table 2), one tSNP () and one SNP previously associated with AMD () demonstrated significant uncorrected p values, but no significant association was found for any VEGFA SNP after correcting for multiple comparisons. Allele distributions for the 20 VEGFR-2 tSNPs showed significant uncorrected p values for three tSNPs, but none remained significant after correcting for multiple comparisons (Table 3). No VEGFR-2 tSNPs were associated with neovascular AMD by genotype distribution (Table 4).
###end p 23
###begin title 24
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Allele distribution for single nucleotide polymorphisms in VEGFA
###end title 24
###begin p 25
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 316 321 316 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
A total of 515 patients with age-related macular degeneration (cases) and 253 ethnically-matched individuals without age-related macular degeneration (controls) were genotyped for nine single nucleotide polymorphisms (SNPs) in the VEGFA gene. The Location in gene column refers to the location of the SNP within the VEGFA gene. The Genomic location column identifies the specific location of each SNP on Chromosome 6. The Variation column indicates the nature of the polymorphism from the normal allele to the variant allele. The frequency of the minor allele for each SNP was compared in cases and controls by the chi-square test. Odds ratios, 95% confidence intervals (CI), and p-values are reported. Adjusted p-values have been corrected for multiple comparisons using the Bonferroni method.
###end p 25
###begin title 26
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Genotype distribution for single nucleotide polymorphisms in VEGFA
###end title 26
###begin p 27
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Genotype analysis of VEGFA single nucleotide polymorphisms (SNPs) was performed by logistic regression, incorporating adjustments for age and gender. Odds ratios (OR), 95% confidence intervals (CI), and p-values are reported by genotype (normal/variant, variant/variant) for each tested SNP. Adjusted p-values have been corrected for multiple comparisons using the Bonferroni method.
###end p 27
###begin title 28
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
Allele distribution for tagging single nucleotide polymorphisms in VEGFR-2
###end title 28
###begin p 29
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 320 327 320 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
A total of 515 patients with age-related macular degeneration (cases) and 253 ethnically-matched individuals without age-related macular degeneration (controls) were genotyped for twenty single nucleotide polymorphisms (SNPs) in the VEGFR-2 gene. The Location in gene column refers to the location of the SNP within the VEGFR-2 gene. The Genomic location column identifies the specific location of each SNP on Chromosome 4. The Variation column indicates the nature of the polymorphism from the normal allele to the variant allele. The frequency of the minor allele for each SNP was compared in cases and controls by the chi-square test. Odds ratios, 95% confidence intervals (CI), and p-values are reported. Adjusted p-values have been corrected for multiple comparisons using the Bonferroni method.
###end p 29
###begin title 30
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
Genotype distribution for tagging single nucleotide polymorphisms in VEGFR-2
###end title 30
###begin p 31
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
Genotype analysis of VEGFR-2 tagging single nucleotide polymorphisms (tSNPs) was performed by logistic regression, incorporating adjustments for age and gender. Odds ratios (OR), 95% confidence intervals (CI), and p-values are reported by genotype (normal/variant, variant/variant) for each tested tSNP. Adjusted p-values have been corrected for multiple comparisons using the Bonferroni method.
###end p 31
###begin p 32
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 130 138 130 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 179 187 179 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 281 288 281 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 414 421 414 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
Linkage disequilibrium-based haplotypes were defined for the VEGFA and VEGFR-2 SNPs, resulting in two haplotype blocks for VEGFA (Figure 1) and five haplotype blocks for VEGFR-2 (Figure 2). Haplotype analysis demonstrated no VEGFA haplotypes to be associated with neovascular AMD (Table 5) but did reveal a mild association of the rarest haplotype (TTT) in VEGFR-2 haplotype block 3 with neovascular AMD (p=0.034, Table 6).
###end p 32
###begin p 33
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Linkage disequilibrium map of VEGFA single nucleotide polymorphisms. Two haplotype blocks (bolded) were identified for the nine single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor (VEGFA) gene. A linkage disequilibrium map of these haplotype blocks was generated using Haploview. Length of each block is provided in kilobases (kb), and pairwise linkage disequilibrium (D') is given for each SNP combination. Dark red shading denotes D' values greater than 0.80, and empty squares indicate D' values of 1.0.
###end p 33
###begin p 34
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 230 237 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
Linkage disequilibrium map of VEGFR-2 tagging single nucleotide polymorphisms. Five haplotype blocks were identified for the 20 tagging single nucleotide polymorphisms (tSNPs) in the vascular endothelial growth factor receptor-2 (VEGFR-2) gene. A linkage disequilibrium map of these haplotype blocks was generated using Haploview. Length of each block is provided in kilobases (kb), and pairwise linkage disequilibrium (D') is given for each SNP combination. Dark red shading denotes D' values greater than 0.80, and empty squares indicate D' values of 1.0.
###end p 34
###begin title 35
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Haplotype analysis of VEGFA
###end title 35
###begin p 36
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 208 220 <span type="species:ncbi:9606">participants</span>
Two haplotype blocks were identified for the tested single nucleotide polymorphisms (SNPs) in VEGFA using Haploview. Haplotype frequencies in neovascular age-related macular degeneration patients (cases) and participants without age-related macular degeneration (controls) are reported with corresponding p-values. Haplotypes with frequencies above 0.01 are included in the table.
###end p 36
###begin title 37
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
Haplotype analysis of VEGFR-2
###end title 37
###begin p 38
###xml 97 104 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 213 225 <span type="species:ncbi:9606">participants</span>
Five haplotype blocks were identified for the tagging single nucleotide polymorphisms (tSNPs) in VEGFR-2 using Haploview. Haplotype frequencies in neovascular age-related macular degeneration patients (cases) and participants without age-related macular degeneration (controls) are reported with corresponding p-values. Haplotypes with frequencies above 0.01 are included in the table.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
We analyzed nine SNPs in VEGFA and 20 tSNPs in VEGFR-2 using a tSNP approach designed to cover both genes. The results of this study show little evidence of association with neovascular AMD in our cohort of 515 Caucasian patients.
###end p 40
###begin p 41
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 625 630 625 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 716 721 716 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 1131 1136 1131 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
Previous investigation of VEGFA and AMD has yielded conflicting results. A few smaller-scale case-control studies have reported significant associations for various SNPs in VEGFA [18-21], but the validity of these results remains unconfirmed [22-24]. The only one of these studies to investigate a large neovascular AMD cohort (n=342) using a comprehensive tSNP approach found no link between VEGFA tSNPs and development of neovascular AMD [22]. More recently, a single haplotype was shown to be weakly associated with neovascular AMD in a moderately-sized cohort (n=211), although no associations were found with individual VEGFA SNPs [25]. In the present study, we found no association between neovascular AMD and VEGFA SNPs or haplotypes. These discrepant findings may be due to inadequate sample size in the early studies or to the ethnic composition of study populations. Results could also be biased by genotyping error or confounding effects due to statistically significant variables such as age, gender, or other SNPs known to be associated with AMD. As a whole, the studies performed to date provide little evidence that VEGFA polymorphisms exert any significant influence on risk of neovascular AMD.
###end p 41
###begin p 42
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 386 393 386 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 719 726 719 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-1</italic>
###xml 731 738 731 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 871 878 871 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 1056 1063 1056 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 403 407 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
This is the first study to investigate the relationship between variants in VEGFR-2 and AMD. One of two receptor tyrosine kinases involved in VEGF signaling pathways, VEGFR-2 mediates the majority of the angiogenic and permeability-enhancing effects of VEGF [17]. The importance of VEGFR-2 in developmental angiogenesis and hematopoiesis, as demonstrated by the abnormal vasculature of VEGFR-2 knockout mice [27], suggests a link between the VEGF/VEGFR-2 pathway and retinal pathology. While VEGF and its receptors play a key role in tumor angiogenesis and other pathological conditions [14,16,28,29], a limited number of gene association studies have been performed for VEGF receptor genes. Recently, polymorphisms in VEGFR-1 and VEGFR-2 were reported to be associated with sarcoidosis, an inflammatory condition with a hypothesized antigenic stimulus [30]. Variants in VEGFR-2 have also been linked with heart disease and may influence the risk of developing breast cancer [31-33]. In our large neovascular AMD cohort, no associations were found for any VEGFR-2 tSNPs by allele or genotype analysis. Haplotype analysis, however, did show a single rare haplotype to be mildly associated with AMD.
###end p 42
###begin p 43
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 123 130 123 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 540 547 540 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 619 626 619 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 711 716 <span type="species:ncbi:9606">human</span>
This study is limited by its retrospective design, which did not allow for assessment of the predictive value of VEGFA and VEGFR-2. However, in light of our negative findings, it is doubtful that a prospective study would contribute significantly to our knowledge base. This study was designed to investigate common polymorphisms that might be associated with neovascular AMD risk, and it remains possible that rare variants with MAFs less than 10% could play a role in neovascular AMD development. Due to tSNP assay failure, two of the 46 VEGFR-2 SNPs with a MAF greater than 10% were poorly tagged. The 20 successful VEGFR-2 tSNPs in our study covered the polymorphisms previously found to be associated with human diseases: ,  (covered by ), , , , and  [30-33].
###end p 43
###begin p 44
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFA</italic>
###xml 349 356 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGFR-2</italic>
In summary, this study is the first to investigate the association of VEGFR-2 polymorphisms with AMD and evaluates VEGFA genetic variants in the largest neovascular AMD cohort to date. Although both VEGF and its receptors have been implicated in the pathophysiology of diseases such as AMD, we found minimal evidence that polymorphisms in VEGFA and VEGFR-2 contribute significantly to risk of neovascular AMD.
###end p 44
###begin title 45
Acknowledgments
###end title 45
###begin p 46
###xml 22 27 <span type="species:ncbi:9606">Human</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
The authors thank the Human Genetics Division Genotyping Core at the Washington University School of Medicine for assisting with genotyping and the physicians of the Barnes Retina Institute for generously contributing their time and patients to this study. This work was supported by the Jahnigen Career Development Award from the American Geriatrics Society (M.A.B.), the Carl M. & Mildred A. Reeves Foundation (M.A.B.), NEI Core Grant 5 P30 EY02687, and a grant from Research to Prevent Blindness to the Washington University School of Medicine Department of Ophthalmology and Visual Sciences.
###end p 46
###begin title 47
References
###end title 47
###begin article-title 48
Prevalence of age-related macular degeneration in the United States.
###end article-title 48
###begin article-title 49
Review of genetics in age-related macular degeneration.
###end article-title 49
###begin article-title 50
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 50
###begin article-title 51
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 51
###begin article-title 52
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 52
###begin article-title 53
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.
###end article-title 53
###begin article-title 54
Susceptibility genes for age-related maculopathy on chromosome 10q26.
###end article-title 54
###begin article-title 55
AMD Genetics Clinical Study Group, Hageman GS, Dean M, Allikmets R. Variant in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
###end article-title 55
###begin article-title 56
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration.
###end article-title 56
###begin article-title 57
Variation in complement factor 3 is associated with risk of age-related macular degeneration.
###end article-title 57
###begin article-title 58
Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration.
###end article-title 58
###begin article-title 59
C3 R102G polymorphism increases risk of age-related macular degeneration.
###end article-title 59
###begin article-title 60
Evaluation of clustering and genotype distribution for replication in genome wide association studies: the age-related eye disease study.
###end article-title 60
###begin article-title 61
The biology of VEGF and its receptors.
###end article-title 61
###begin article-title 62
Age-related macular degeneration: experimental and emerging treatments.
###end article-title 62
###begin article-title 63
Regulation of angiogenesis via vascular endothelial growth factor receptors.
###end article-title 63
###begin article-title 64
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
###end article-title 64
###begin article-title 65
Functional candidate genes in age-related macular degeneration: significant association with VEGF, VDLR, and LRP6.
###end article-title 65
###begin article-title 66
VEGF polymorphisms are associated with neovascular age-related macular degeneration.
###end article-title 66
###begin article-title 67
Vascular Endothelial Growth Factor Gene Polymorphisms in Age-related Macular Degeneration.
###end article-title 67
###begin article-title 68
Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population.
###end article-title 68
###begin article-title 69
A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration.
###end article-title 69
###begin article-title 70
Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study.
###end article-title 70
###begin article-title 71
Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss.
###end article-title 71
###begin article-title 72
VEGF and age-related macular degeneration.
###end article-title 72
###begin article-title 73
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 73
###begin article-title 74
###xml 72 76 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.
###end article-title 74
###begin article-title 75
VEGF-targeted therapy: therapeutic potential and recent advances.
###end article-title 75
###begin article-title 76
###xml 134 142 <span type="species:ncbi:9606">patients</span>
Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
###end article-title 76
###begin article-title 77
VEGF gene haplotypes are associated with sarcoidosis.
###end article-title 77
###begin article-title 78
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KDR</italic>
Polymorphisms of KDR gene are associated with coronary heart disease.
###end article-title 78
###begin article-title 79
Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.
###end article-title 79
###begin article-title 80
Association of polymorphisms of angiogenesis genes with breast cancer.
###end article-title 80

